Evolved Machines Enters Into License Agreement with Nanosys

Evolved Machines, Inc. and Nanosys Inc. today announced that Evolved Machines has entered into a sublicense agreement with Nanosys for a portfolio of patents and patent applications related to the use of nanotubes and nanowires for artificial olfaction and chemical sensing.

The core intellectual property involves a wide range of applications in nanotechnology, nanomaterials and the use of nanotube and nanowire-based field effect transistors (FET's) as biosensors. Nanosys owns an extensive portfolio of IP around multiple aspects of nanotechnology including basic nanowire compositions, nanowire synthesis and the use of nanowires and other nanostructures for many applications.

Under terms of the agreement, Evolved Machines has secured or has obtained options to secure a variety of exclusive, worldwide rights among which are the use of DNA-functionalized nanowire or nanotube-based sensor arrays for the detection and/or identification of an analyte or analytes in the gas and/or liquid phase.

Evolved Machines, in partnership with its affiliate iSense, LLC, is developing nanotube-based field effect transistors (FETS) functionalized by DNA as highly sensitive sensors across a very wide range of targets. "The DNA sequence-dependent nature of binding affinity for these devices enables highly diverse analyte discrimination, while the nanotube transistor imparts great sensitivity. Further, this class of sensor is completely reversible across a wide range of analytes, allowing repeated use and enabling the first devices capable of remote autonomous multi-analyte sensing," according to Dr. Paul A. Rhodes, Evolved Machines CEO.

Working in partnership with its affiliate, iSense, Evolved Machines is developing a wide range of immediate high-value applications ranging from airport, port and transit screening, to first responder domestic and military hand-held sets, to medical diagnosis, to autonomous 24/7 monitoring of the water supply and of containers on-board ship.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback